The most clinically consequential of the findings concerns Fuchs endothelial corneal dystrophy, a progressive genetic disease of the cornea’s inner cell layer that affects an estimated 4 to 7 percent of people in the United States and accounts for roughly one-third of the corneal transplants performed each year. The inner endothelium works as a fluid pump that keeps the cornea clear; when its cells progressively fail, the cornea swells, clouds, and vision deteriorates. For decades, the standard remedy for advanced disease has been replacement of the cornea with donor tissue, a strategy that works but carries the logistical, immunological, and lifelong follow-up burdens of transplant surgery.

A surgical alternative known as Descemet stripping only, or DSO, was pioneered in the United States by Dr. Colby. The procedure removes only the diseased central sheet of endothelial cells, leaving the patient’s healthier peripheral cells to migrate inward and repopulate the cornea. The approach eliminates the need for donor tissue in suitable patients, but recovery depends on how quickly and completely those remaining cells repopulate the central cornea. The new results address precisely that bottleneck, using a topical drug to accelerate the cellular healing process after surgery.

The phase 2 trial, known as Ripasudil (K-321-201), was the first multicenter, placebo-controlled randomized study of a Rho-associated protein kinase, or ROCK, inhibitor eyedrop administered after DSO. ROCK inhibitors are known to promote endothelial cell migration and proliferation and to discourage the cellular enlargement that marks endothelial failure. In the study, 65 patients at 38 sites across five countries were randomly assigned to receive the topical medication four times daily, twice daily, or a placebo for 12 weeks after undergoing DSO. Patients receiving the medicine achieved a central endothelial cell density of 531 cells per square millimeter, compared with 228 in the placebo group, indicating substantially better preservation and repopulation of the critical pumping layer.

The clinical outcomes were even more striking than the cell counts. Corneal swelling cleared completely in 17 of 21 patients using ripasudil, or 81 percent, compared with 2 of 22 patients, or 9 percent, in the placebo arm. Only 10 percent of patients in the medication group required a rescue corneal transplant, versus 27 percent of those on placebo. More than 95 percent of participants completed the one-year study, and no patient stopped treatment because of a side effect. The paper, co-authored by Dr. Colby, appeared as an American Ophthalmological Society thesis in the American Journal of Ophthalmology, and Dr. Colby presented the findings along with updates on the ongoing phase 3 trials during the Cornea and Eye Banking Forum. In her remarks, she emphasized that what matters most to patients is not a cell count but how quickly and predictably their vision returns and whether they can avoid a transplant altogether, adding that the trial provides high-quality evidence that a simple eye drop can do exactly that after DSO.

A second major theme at the meeting was corneal neovascularization, the abnormal growth of blood vessels into the normally clear cornea, a condition that affects an estimated 1.4 million people worldwide each year and is unilateral in about 76 percent of cases. It is most often driven by infectious keratitis, trauma, contact lens complications, and other ocular surface disease. Vascular invasion of the cornea not only degrades visual clarity directly but also dramatically raises the risk of rejection if the patient later needs a corneal transplant. Mohammad H. Dastjerdi, associate professor of ophthalmology at NYU Grossman School of Medicine, served as senior instructor for a course at the academy meeting outlining a staged treatment arsenal matched to the biology of the offending vessels.

The course’s central principle is that not all corneal vessels behave alike, and therapy must be matched to vessel maturity after the underlying trigger is treated. Newly formed, active vessels respond best to corticosteroids and anti-VEGF therapy such as bevacizumab, which suppresses the vascular growth signals sustaining them. Mature, lipid-laden vessels, which can be fully encased in protective pericytes, typically require destructive approaches such as fine-needle diathermy or mitomycin intravascular chemoembolization, abbreviated MICE. Faculty presented pooled data from an international retrospective series of 100 eyes treated with MICE between 2021 and 2024 after medical therapy failed. Surgeons reported full or partial vessel regression in approximately 81 percent of eyes at six to 12 months, and masked image analysis showed a mean 56 percent reduction in vessel area over the same interval. Best-corrected vision improved significantly, about 22 percent of eyes required repeat treatment, no infections occurred, and among 18 eyes that went on to corneal transplant, no rejections or graft failures were reported over at least one year of follow-up. Dr. Dastjerdi stressed that corneal neovascularization is not one disease and should not be met with one treatment, because the depth, caliber, and above all the age of the vessels dictate which tool to reach for, and combination therapy is often what finally breaks the cycle.

A third presentation sounded an urgent diagnostic alarm. At the Cornea and Eye Banking Forum, Dr. Dastjerdi described a retrospective case series of 17 adults with laboratory-confirmed vitamin A deficiency who developed corneal epithelial defects, ulceration, corneal melting, descemetocele, or perforation, yet none showed the classic outward signs clinicians are trained to recognize, such as conjunctival xerosis, Bitot’s spots, or clinically apparent corneal drying. The cohort included nine women and eight men. Nine patients, or 53 percent, presented with a descemetocele or frank corneal perforation, and every perforation occurred in a patient whose vitamin A level was below 10 micrograms per deciliter. Eight patients, or 47 percent, required tectonic keratoplasty, a structural corneal graft performed to preserve the integrity of the eye, and one additional patient died before planned surgery. Three patients, or 18 percent, died of systemic disease complications before their eye disease could be stabilized, and blood tests across the cohort revealed low levels of albumin, hemoglobin, magnesium, calcium, and vitamin D. Dr. Dastjerdi explained that these patients did not look like the textbook picture of vitamin A deficiency, which is precisely why the diagnosis is missed until the cornea has already melted, and he urged that unexplained corneal breakdown or ulceration alongside low albumin, anemia, or low magnesium should prompt a serum vitamin A level.

The program’s most ambitious offering looked beyond the cornea entirely. Vaidehi S. Dedania, associate professor of ophthalmology at NYU Grossman School of Medicine, participated in a symposium reviewing progress toward total human eye allotransplantation, or THEA, a frontier concept aimed at transforming treatment for irreversible blindness. Dr. Dedania was part of the NYU Langone team that completed the world’s first successful whole-eye and partial-face transplant in 2023. The obstacles to whole-eye transplantation are formidable: the complexity of orbital anatomy, and the intricacies and sensitivities of the optic nerve and retinal structures make functional restoration far harder than anatomical replacement. NYU Langone is part of a 56 million dollar effort through the federal Advanced Research Projects Agency for Health’s VISION Strategies for Whole Eye Transplant program, whose name captures the key research pillars of viability, imaging, surgical technique, immunomodulation, ocular preservation, and neuroregeneration. At the symposium, speakers discussed innovations in medical devices, novel surgical methods combined with advances in biostasis and perfusion, the newest successes in promoting long-distance optic nerve regeneration, and improvements in immunomodulation to prevent rejection.

Taken together, the New Orleans presentations illustrate a discipline in transition, in which the cornea is increasingly treated pharmacologically rather than replaced, vascular disease is managed by stratifying therapy to the biology of individual vessels, clinicians are being taught to detect a blinding nutritional disorder before it destroys tissue, and the first steps toward transplanting the entire human eye are being mapped through federally funded, multidisciplinary research. For patients with Fuchs dystrophy, the ripasudil results suggest that a future involving eyedrops rather than donor tissue is coming into view, while the broader message of the meeting is that careful diagnosis, staged therapy, and audacious long-horizon science can advance together within a single clinical enterprise.

Subject of Research: Corneal disease therapies and whole-eye transplant advances presented at the American Academy of Ophthalmology 2026 meeting

Article Title: NYU Langone Health ophthalmology faculty present advances in eye care at AAO 2026

Article References: NYU Langone Health ophthalmology faculty present advances in eye care at AAO 2026. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: corneal transplant, Fuchs endothelial corneal dystrophy, Descemet stripping only, ripasudil, ROCK inhibitor, corneal neovascularization, anti-VEGF therapy, vitamin A deficiency, whole-eye transplant, optic nerve regeneration, ARPA-H, ophthalmology

The clinical stakes are considerable. Although meibomian gland carcinoma accounts for only about 5 to 10 percent of eyelid tumors, reported mortality rates range from 15 to 25 percent, a striking figure for so uncommon a disease. The tumor arises from the meibomian glands, modified sebaceous structures embedded in the tarsal plate of the eyelid, and it behaves badly in every sense. It grows in a multifocal pattern, spreads along the conjunctival epithelium in a characteristic skip or jump fashion that leads surgeons to underestimate its true extent, and frequently returns after resection with positive margins. Once it reaches lymph nodes or distant organs, five-year disease-specific survival falls below 30 percent. Clinicians widely regard it as the most difficult eyelid tumor to diagnose and manage.

Part of the difficulty is that the tumor’s lineage identity is fragile outside the body. Meibomian gland cells carry lipid-rich cytoplasm, terminal sebaceous differentiation programs, and tightly regulated androgen receptor-dependent transcription networks. Under conventional two-dimensional culture conditions these features collapse quickly, producing dedifferentiated cells that no longer resemble the tumor the surgeon removed. The only published human meibomian gland carcinoma cell line, established by Zhang and colleagues, could be maintained for roughly 20 passages before fibroblast overgrowth took over, a familiar failure mode of primary culture. Most of what is known about the disease therefore comes from retrospective clinicopathological studies and static immunohistochemistry of formalin-fixed specimens, which capture structure but not function.

Therapeutic progress has been equally constrained. Conventional chemotherapy agents, including platinum compounds, taxanes, 5-fluorouracil, and mitomycin C, achieve modest response rates and rarely deliver durable control in advanced disease. Genomic profiling studies have identified recurrent alterations in PTGS2, HER2, PIK3CA, and PTEN, along with Hedgehog signaling changes and DNA mismatch repair defects, but without functional platforms to validate these findings, they have not translated into targeted therapies. The authors argue that the absence of scalable, patient-derived models preserving lineage identity, tumor heterogeneity, and functional plasticity has become the central bottleneck in the field, a greater obstacle than the lack of genomic data itself.

Conditional reprogramming, first described by Liu and colleagues in 2012, offers a way around this bottleneck. The technique co-cultures primary epithelial cells with gamma-irradiated mouse 3T3-J2 feeder fibroblasts in F/2 medium supplemented with the Rho-associated kinase inhibitor Y-27632. ROCK inhibition prevents anoikis and cytoskeletal tension-induced apoptosis, while the feeder layer supplies paracrine signals and extracellular matrix components that sustain epithelial survival. Together these inputs converge on pathways governing actin dynamics, cell-cell adhesion, and stress responses, effectively decoupling proliferative capacity from terminal differentiation. The result is a reversible, non-neoplastic, stem-like proliferative state: cells divide furiously, yet they retain lineage-specific transcriptional programs and genomic integrity, and they are not driven toward malignant transformation.

The numbers are remarkable. Conditional reprogramming cultures expand 10 to 100 times faster than conventional epithelial cultures, yielding between 100 million and a billion cells from a 2-millimeter biopsy in under three weeks. Multiple studies have documented high genomic fidelity across extended passages, including preserved variant allele frequencies and an absence of de novo chromosomal aberrations. Equally important is reversibility: remove the feeder layer or the ROCK inhibitor and the cells promptly exit the proliferative state, re-engage native differentiation programs, and rebuild tissue-specific architecture. This distinguishes the method from induced pluripotent stem cell reprogramming and oncogene-based immortalization, both of which erase lineage memory. The system can also generate matched tumor and adjacent normal epithelial cultures from the same patient, creating isogenic pairs that minimize inter-individual genetic variability and allow direct comparison of oncogenic signaling and drug responses.

Over the past decade the platform has proven itself across epithelial cancers. In bladder cancer, Kettunen and colleagues showed that ex vivo drug-response profiles from conditionally reprogrammed cells concorded with clinical outcomes in a personalized screening platform paired with patient-derived xenografts. In prostate cancer, paired tumor and normal cultures revealed tumor-selective synergy between docetaxel and radiation, defining a therapeutic window that spares healthy epithelium. In colorectal cancer, a dose-response matrix approach assessed combined sensitivity to 5-fluorouracil and oxaliplatin, marking the first functional assay to guide adjuvant chemotherapy selection in that disease. Large-scale biobanks built with the technology, including more than 120 head and neck squamous carcinoma lines coupled to whole-exome sequencing and a gastric cancer repository spanning 32 patients, demonstrate its scalability for rare specimens.

Ophthalmic applications have been slower to arrive but are encouraging. Conditionally reprogrammed human limbal epithelial cells have maintained normal karyotype and stable drug-toxicity profiles across passages, validating their use in ocular surface safety screening. The technology has converted human fibroblasts into retinal pigment epithelium-like cells within two weeks, far faster than pluripotent stem cell protocols, and has sustained papillomavirus-positive canine eyelid epithelium for antiviral testing. In conjunctival fornix epithelial cells, the mucolytic drug bromhexine stimulated MUC5AC secretion and lipid-droplet production, hinting at therapeutic targets for ocular lubrication disorders. Most relevant to eyelid oncology, Lee and colleagues used conditional reprogramming to generate the first authenticated trio of ocular adnexal sebaceous carcinoma lines, preserving patient-specific mutations, adipophilin-positive lipid vacuoles, and MYC overexpression, with full validation by short tandem repeat profiling and next-generation sequencing within five passages. Functional testing of mitomycin C, 5-fluorouracil, and the glutamine-metabolism inhibitor DON each induced dose-dependent apoptosis and differentiation, an immediate proof of concept in a historically model-poor disease.

For meibomian gland carcinoma specifically, the review describes a practical workflow. Fresh surgical specimens are minced and enzymatically dissociated, then seeded onto irradiated 3T3-J2 feeder layers in Y-27632-supplemented medium. Validation relies on immunophenotypic markers including cytokeratins, epithelial membrane antigen, androgen receptor, adipophilin, Ki-67, and p63, alongside functional assays in which withdrawal of the ROCK inhibitor tests whether lipid metabolism and sebaceous differentiation can be restored. The authors also stress structured quality control: short tandem repeat authentication, histological correlation with the parental tumor, confirmation of driver alterations and copy-number profiles, longitudinal tracking of tumor-specific variants, and defined passage limits. Such measures guard against the field’s known pitfalls, including preferential expansion of non-malignant epithelium, clonal selection in small biopsies, and possible epigenetic drift during prolonged culture.

Limitations remain real. The mouse feeder layer introduces interspecies signaling that complicates interpretation, and the cultures lack the immune, stromal, and vascular components of the native tumor microenvironment, restricting studies of immune evasion and therapy-induced immune modulation. The authors propose mitigation through pathology-guided sampling, tumor-cell enrichment, molecular monitoring, and the development of feeder-free and hybrid co-culture systems. Looking ahead, they envision conditional reprogramming serving as the upstream expansion step that feeds organoid culture, patient-derived xenografts, multi-omics profiling, and artificial intelligence-assisted analysis of drug-response matrices and imaging phenotypes. In a disease too rare for randomized trials, where surgical specimens are small and fragmented and engraftment rates in xenograft models are low, that combination could anchor functional precision oncology, guide eye-sparing treatment strategies, and finally give clinicians a way to test therapies on living cells from the very tumors they are trying to beat.

Subject of Research: Use of conditional reprogramming cell culture technology to develop patient-derived preclinical models of meibomian gland carcinoma and other eyelid tumors.

Article Title: Conditional reprogramming in eyelid tumors: bridging the model gap in meibomian gland carcinoma

Article References: Conditional reprogramming in eyelid tumors: bridging the model gap in meibomian gland carcinoma. (n.d.). https://doi.org/10.1007/s44272-026-00057-3

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00057-3

Keywords: conditional reprogramming, meibomian gland carcinoma, eyelid tumors, sebaceous carcinoma, patient-derived models, ROCK inhibitor, precision oncology, drug sensitivity testing, ocular oncology, organoids, tumor biobanking, translational research